APOE4-dependent association between metformin use and Alzheimer's disease-related cortical thickness in older adults with type 2 diabetes - PubMed
3 hours ago
- #Metformin
- #Alzheimer's Disease
- #APOE4
- Metformin use is associated with greater Alzheimer's disease (AD)-signature cortical thickness (AD-CT) in older adults with type 2 diabetes mellitus (T2DM).
- The association between metformin use and AD-CT is moderated by APOE4 status, with benefits observed primarily in APOE4 non-carriers.
- Metformin use was not significantly associated with amyloid-β (Aβ), tau deposition, or white matter hyperintensity (WMH) volume.
- APOE4 non-carriers using metformin showed better global cognition alongside greater AD-CT.
- The study suggests metformin may have neuroprotective effects independent of amyloid or tau pathology, particularly in individuals without the APOE4 genetic risk factor.